HansaBioMed Report issue

For profit Phase 2 Phase 3
Founded: Tallinn Estonia (2007)
Status: Acquired by Lonza (2017)

Organization Overview

First Clinical Trial
2013
NCT01802697
First Marketed Drug
2017
articaine (Septocaine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hansa Biopharma AB | Hansa Medical AB | HANSAMED INC